Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Recent advances in cell-surface glycan engineering and its biological applications.

Chemical Society reviews·2026

Same author

Targeting MAFB potentiates immune checkpoint inhibitor efficacy by reprogramming tumor-associated macrophages to an M1-like phenotype in colorectal cancer.

Translational research : the journal of laboratory and clinical medicine·2026

Same author

In Situ Substrate Temperature Control for High-Performance Blue-Emitting OLEDs with Extended Operational Lifetime.

ACS applied materials & interfaces·2025

Same author

Submicromolar fluorescence 'turn-on' detection of fluoride anions using <i>meso</i>-(tetra-aryl) calix[4]pyrrole.

Organic & biomolecular chemistry·2024

Same author

Strategy for Construction of Homogeneous Glycoproteins in Mammalian Cells.

Bioconjugate chemistry·2024

Same author

Selective fluorescent labeling of cellular proteins and its biological applications.

Chemical Society reviews·2024

Search research articles

Related Experiment Video

Updated: Oct 29, 2025

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

A triple-targeting delivery system carrying two anticancer agents.

Hui Li¹, Chang-Hee Lee¹, Injae Shin¹

¹Department of Chemistry, Yonsei University, Seoul 03722, Republic of Korea. injae@yonsei.ac.kr.

Organic & Biomolecular Chemistry

|July 8, 2021

Summary

A novel triple-targeting delivery system releases two anticancer agents, apoptozole and doxorubicin, specifically within tumors. This targeted approach enhances drug delivery by utilizing tumor-specific biomarkers for improved cancer treatment selectivity.

More Related Videos

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Related Experiment Videos

Last Updated: Oct 29, 2025

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Area of Science:

Biomedical Engineering
Drug Delivery Systems
Oncology

Background:

Improving tumor selectivity is crucial for effective cancer therapy.
Conventional chemotherapy often causes systemic toxicity due to lack of targeted delivery.
Tumors exhibit unique microenvironmental conditions, such as elevated hydrogen peroxide (H2O2) and cathepsin B levels.

Purpose of the Study:

To design and synthesize a novel triple-targeting delivery system for enhanced tumor selectivity.
To co-deliver two distinct anticancer agents, apoptozole (Az) and doxorubicin (Dox), using this system.
To investigate the targeted release mechanism of the anticancer agents within the tumor microenvironment.

Main Methods:

Synthesis of a triple-targeting delivery system, denoted as Oct-FK(PBA-Az)-Dox.
Characterization of the delivery system's properties and drug loading.
In vitro evaluation of the drug release kinetics in response to tumor-specific stimuli (H2O2 and cathepsin B).

Main Results:

The successful design and synthesis of the Oct-FK(PBA-Az)-Dox triple-targeting delivery system.
Demonstration that both apoptozole and doxorubicin are effectively liberated from the delivery system.
Confirmation that drug liberation is triggered by the presence of both H2O2 and cathepsin B, common in tumor tissues.

Conclusions:

The developed Oct-FK(PBA-Az)-Dox system shows promise for targeted cancer therapy.
The system's ability to release drugs in response to tumor-specific biomarkers enhances selectivity.
This targeted drug delivery approach could potentially reduce side effects and improve therapeutic outcomes in cancer treatment.